Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

17.2K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
17.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and Safety of Momelotinib in Myelofibrosis: A Systematic Review and Meta-Analysis With a Focus on Anemia Outcomes.

Journal of hematology·2025
Same author

Beyond The Usual Suspects: Primary Breast Lymphoma Incidentally Detected With Routine Mammographic Screening.

Journal of investigative medicine high impact case reports·2025
Same author

Diagnosis of Angioimmunoblastic T Cell Lymphoma After Receiving First Dose of Pfizer/BioNTech (BNT162b2) Vaccine: A Case Report.

Journal of investigative medicine high impact case reports·2024
Same author

Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Review of Current Literature and Case Discussion.

Journal of investigative medicine high impact case reports·2022
Same author

First Case of Nodular Localized Primary Cutaneous Amyloidosis Treated With Bortezomib and Dexamethasone.

Journal of investigative medicine high impact case reports·2021
Same author

Effect of Tart Cherry on Aromatase Inhibitor-Induced Arthralgia (AIA) in Nonmetastatic Hormone-Positive Breast Cancer Patients: A Randomized Double-Blind Placebo-Controlled Trial.

Clinical breast cancer·2021
Same journal

Revisiting the Immunological Landscape of Locoregional Therapies for Gastrointestinal Cancers: A Shift Toward Interventional Immuno-Oncology.

Current oncology reports·2026
Same journal

Anti-PD-1 Combinations: Triplets and Beyond.

Current oncology reports·2026
Same journal

Sacituzumab Tirumotecan Across Gynecologic Malignancies: One Target, Multiple Diseases.

Current oncology reports·2026
Same journal

Clusterin in Head and Neck Squamous Cell Carcinoma: Diagnostic, Prognostic, and Therapeutic Implications.

Current oncology reports·2026
Same journal

Cardiac Risk Without a Roadmap: Lack of Evidence-Based Guidance for Cardiovascular Toxicity of T-Cell Redirecting Therapies.

Current oncology reports·2026
Same journal

Current Understanding of CHIP's Immunobiological Footprint with A Focus on Gastrointestinal Disorders: A Review of the Literature.

Current oncology reports·2026
See all related articles

Related Experiment Video

Updated: Feb 22, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

12.4K

Double-Hit Large B Cell Lymphoma.

Yousef Khelfa1, Yehuda Lebowicz1, Muhammad Omer Jamil2

  • 1Division of Hematology and Oncology, Department of Internal Medicine, Marshall University School of Medicine-Edwards Comprehensive Cancer Center, 1400 Hal Greer Boulevard, Huntington, WV, 25701, USA.

Current Oncology Reports
|September 28, 2017
PubMed
Summary
This summary is machine-generated.

Diffuse large B cell lymphoma (DLBCL) is a common non-Hodgkin lymphoma (NHL). Double-hit lymphoma (DHL), an aggressive subtype, shows poor outcomes with standard RCHOP chemotherapy, necessitating further research into optimal treatments.

Keywords:
BCL2BCL6DLBCLDouble-hit lymphomaMYC

More Related Videos

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma
07:52

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma

Published on: January 9, 2019

20.6K
Murine Model of CD40-activation of B cells
12:24

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

13.3K

Related Experiment Videos

Last Updated: Feb 22, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

12.4K
Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma
07:52

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma

Published on: January 9, 2019

20.6K
Murine Model of CD40-activation of B cells
12:24

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

13.3K

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Diffuse large B cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma (NHL), representing 25% of cases.
  • DLBCL is a heterogeneous disease with frequent mutations in BCL2, BCL6, and MYC.
  • Double-hit lymphoma (DHL) is an aggressive DLBCL subtype characterized by MYC rearrangement with BCL2 or BCL6 rearrangement, presenting a significant unmet treatment need.

Purpose of the Study:

  • To review the current understanding and treatment landscape of Double-hit lymphoma (DHL).
  • To highlight the limitations of current treatment strategies and the need for further clinical investigation.

Main Methods:

  • Review of existing literature on DLBCL and DHL.
  • Analysis of retrospective data on treatment efficacy for DHL.
  • Identification of gaps in prospective clinical trials for DHL.

Main Results:

  • DHL is associated with poor outcomes when treated with standard RCHOP chemotherapy.
  • Aggressive regimens like DA-EPOCH and hyper CVAD show potential efficacy in retrospective studies.
  • There is a lack of consensus on the optimal treatment strategy for DHL.

Conclusions:

  • Optimal treatment for DHL remains undefined, with current standard therapies yielding poor results.
  • More aggressive treatment regimens may offer improved outcomes, but require further prospective validation.
  • Further clinical trials, including novel agents, are crucial to improve outcomes for DHL patients.